CCRAS transfers Ayush-64 drug technology to 46 companies
The Central Council for Research in Ayurvedic Sciences (CCRAS) has transferred the technology of Ayush-64 to 46 companies. Ayush-64 is an effective drug in mild and asymptomatic and mild to moderate cases of COVID-19.
Ministry of Ayush in a statement said that before the first wave of COVID, seven companies including IMPCL, the manufacturing unit of the Ministry of Ayush, were responsible for manufacturing Ayush-64.
It said, now the technology has been transferred to 39 companies, taking this figure to 46. This move will lead to an increase in its production and will also make it easier to meet its demand.
Till date, no case of side effects for this medicine have been reported, yet experts suggest taking it only after consulting the doctors. The Ministry said that during the first wave of COVID, a clinical trial was conducted with the Ministry of Ayush and the Council of Scientific and Industrial Research (CSIR), in which it was revealed that Ayush-64 is a very beneficial medicine for COVID patients.
So far, eight clinical trials have been done on this, in which Ayush-64 was administered on 63 thousand patients quarantined at home and the drug was found beneficial in this trial. There were also five random and two single studies in eight clinical trials, where patients were given only Ayush-64 medicine.